IP Library Granted Patent US 9,080,218
Granted Patent B2
US 9,080,218 · App. 13/526,469 · Granted Jul 14, 2015

HIV type and subtype detection

Inventors: Marie-Philippe Biron (Asnieres-sur-Seine, FR); Alain Horvais (Herblay, FR)
Assignee: BIO-RAD INNOVATIONS
C12Q1/703C12Q1/686
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,080,218
App. No.
13/526,469
Granted
Jul 14, 2015
Kind
B2
Abstract

The present invention relates to the detection of HIV by amplification and PCR-based methods.

Claims (23)

1. An amplicon obtainable by amplification from a HIV-containing sample with a primer of SEQ ID NO: 9 and a primer of SEQ ID NO: 24, wherein said amplicon is bound to at least one HIV nucleic acid, which comprises a fluorophore.

2. An amplicon obtainable by amplification from a HIV-containing sample with a primer of SEQ ID NO: 148 and a primer of SEQ ID NO: 170, wherein said amplicon is bound to at least one HIV nucleic acid, which comprises a fluorophore.

3. A set of oligonucleotides, comprising the oligonucleotides of SEQ ID NOs: 148 and 170, wherein said set further comprises at least one HIV nucleic acid, which comprises a fluorophore.

4. A set of oligonucleotides, comprising the oligonucleotides of SEQ ID NOs: 9 and 24, wherein said set further comprises at least one HIV nucleic acid, which comprises a fluorophore.

5. A set of oligonucleotides, which comprises at least two oligonucleotides, the respective sequences of which are structurally suitable as forward and reverse primers, respectively, for annealing to the L20587 HIV1-O reference isolate at such positions that they specifically amplify from said HIV reference isolate a sequence selected from the group consisting of SEQ ID NOs: 4 and 310-311 and the complementary sequences thereof, and which further comprises the oligonucleotides of SEQ ID NOs: 9 and 24, wherein said set further comprises at least one HIV nucleic acid which comprises a fluorophore.

6. A composition, which comprises:

at least one amplicon obtainable by amplification from a HIV-containing sample with a primer of SEQ ID NO.: 148 and a primer of SEQ ID NO: 170, wherein said amplicon is bound to at least one HIV nucleic acid, which comprises a fluorophore,

and which further comprises

at least two oligonucleotides, the respective sequences of which are structurally suitable as forward and reverse primers, respectively, for annealing to the K03455 HIV1-M reference isolate at such positions that they specifically amplify from said HIV reference isolate a sequence selected from the group consisting of:

SEQ ID NOs: 306-308 and

the complementary sequences thereof.

7. The amplicon of claim 1 , which is bound to a heat-activable polymerase, wherein said heat-activable polymerase is activable at 95° C.

8. The amplicon of claim 2 , which is bound to a heat-activable polymerase is activable at 95° C.

9. The set of claim 3 , which is bound to a activable polymerase, wherein said heat-activable polymerase is activable at 95° C.

10. The set of claim 4 , which is bound to a heat-activable polymerase, wherein said heat-activable polymerase is activable at 95° C.

11. The set of claim 5 , which is bound to a heat-activable polymerase, wherein said heat-activable polymerase is activable at 95° C.

12. The composition of claim 6 , which is bound to a heat-activable polymerase, wherein said heat-activable polymerase is activable at 95° C.

13. The amplicon of claim 1 , which is bound to a heat-activable polymerase, wherein said heat-activable polymerase is the Thermus aquaticus polymerase, or the Thermococcus litoralis polymerase, or the Pyrococcus furiosius polymerase.

14. The amplicon of claim 2 , which is bound to a heat-activable polymerase. wherein said heat-activable polymerase is the Thermus aquaticus polymerase, or the Thermococcus litoralis polymerase, or the Pyrococcus furiosius polymerase.

15. The set of claim 3 , which is bound to a heat-activable polymerase, wherein said heat-activable polymerase is the Thermus aquaticus polymerase, or the Thermococcus litoralis polymerase, or the Pyrococcus furiosius polymerase.

16. The set of claim 4 , which is bound to a heat-activable polymerase, wherein said heat-activable polymerase is the Thermus aquaticus polymerase, or the Thermococcus litoralis polymerase, or the Pyrococcus furiosius polymerase.

17. The set of claim 5 , which is hound to a heat-activable polymerase, wherein said heat-activable polymerase is the Thermus aquaticus polymerase, or the Thermococcus litoralis polymerase, or the Pyrococcus furiosius polymerase.

18. The composition of claim 6 , which is bound to a heat-activable polymerase, wherein said heat-activable polymerase is the Thermus aquaticus polymerase, or the Thermococcus litoralis polymerase, or the Pyrococcus furiosius polymerase.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2019
From: BIO-RAD INNOVATIONS
To: BIO-RAD EUROPE GMBH
Reel/Frame 049122/0754 →
Priority Claims (1)
EP 04291402 · Jun 4, 2004 · regional
Continuity (2)
Division 11628326
Related Publication 20120283131A1 · Nov 8, 2012